Durham, NC – Phase Bioscience, Inc., a development stage biotechnology company, announced today that it has successfully raised an additional $5.4 million in Series B financing, bringing the total Series B round to $6.6 million.
Drug Discovery and Development Company Focused on Metalloenzymes Closes Series A Round
Research Triangle Park , NC – Viamet Pharmaceuticals Inc., a biotechnology company targeting metalloenzymes in the fields of infectious disease, inflammation and oncology, announced today that it has closed a $4 million Series A financing round.
DURHAM , NC – Hatteras Venture Partners announced today the first closing of its third venture capital fund, Hatteras Venture Partners III, LP (HVP III). The Fund has secured commitments for $60 million to invest in seed and early-stage companies in biopharmaceuticals, medical devices, diagnostics and related opportunities in human medicine. The ultimate fund size is expected to be $100 million. HVP III may invest in opportunities throughout the country but will focus on forming and leading companies in the southeastern United States, where the level of National Institutes of Health-funded research is high but the availability of early-stage venture capital is limited.